ll28 / iStockphoto.com
Frazier Healthcare Partners has been responsible for creating and investing in multiple biotech companies, developing products from novel antibiotics to cancer therapies. James Topper, Frazier’s managing general partner, explains the firm’s philosophy.
Bringing back big returns on investments is the main goal of venture capitalism. But for James Topper, managing general partner of Frazier Healthcare Partners, there is more that drove him to venturing into life sciences: he finds it rewarding to work with biotech companies as they release drugs that benefit patients.
“The thing I’m most proud of is having been involved in multiple successful venture capital investments in the biotech space together with my colleagues. Many of these have resulted in the development of drugs which have made it to the market and are now benefiting hundreds of thousands of patients,” says Topper.
“All our companies are regulated by the Food and Drug Administration (FDA) and ultimately have to pass scrutiny by that organisation to be successful for the long term.”
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 2017, James Topper, biotech, Frazier Healthcare Partners, venture capital, investment, drug development, antibiotics, cancer therapies,